LASERS IN DENTAL TREATMENT WITHOUT NEEDLES AND DRILLS
Dr Omar Zuaiter
Co-Founder & Chief Executive Officer, Dentroid
Alaa Habeb
Co-Founder & Chief Technology Officer, Dentroid
Professor Laurence Walsh
Chief Dental Officer, Dentroid &
Emeritus Professor, School of Dentistry, University of Queensland &
Adjunct Professor, Griffith University, Queensland
Professor Heiko Spallek
Member Scientific Advisory Committee, Dentroid &
Head of School and Dean of The University of Sydney School of Dentistry
BENCH SIDE STORY CASE STUDY
Filmed in Brisbane, Canberra & Sydney | December 2024
In 2017, Dr. Omar Zuaiter and Alaa Habeb launched Dentroid, a dental technology startup with a mission to make dentistry a kinder and friendlier experience for patients and dentists using photonics (using laser technology) and robotics, as alternatives to needles, drills and sprays. The vision for the startup is to have dentistry adopt laser technology, addressing the root causes of dental pain & anxiety, and create a pain-free dental experience.
Dentroid is pioneering the adoption of femtosecond lasers in dentistry which will be their first surgical application outside eye surgery. Unlike conventional dental lasers or rotary instruments, femtosecond lasers have a very unique ability to precisely cut through the most resistant materials without requiring cooling or causing thermal damage. This “cold cutting” creates convenience for the patient, clearer vision for the practitioner and a cleaner environment in the office without microbes laden droplets.
A key distinctive feature of femtosecond laser in “cold cutting” is that it leaves the underlying tissues unharmed with the aim of supporting faster healing with less postoperative complications.
Dentroid envisages femtosecond lasers, combined with their patented miniaturised robotic technology will change the way dental tissues and restorative materials are prepared, processed and bonded not only in clinics but also in dental labs.
To support this mission, Dentroid has assembled a multidisciplinary team of world-renowned experts in dentistry and medicine, engineering, robotics, physics, medical sciences and AI informatics together with commercialisation and growth minds who helped scale startups grow to much larger organisations.
In this Bench Side Story Case Study release, we spoke with some of the key people involved in Dentroid mission and commercialisation journey.
FORWARD LOOKING STATEMENTS
This case study may contain projections and forward-looking statements that involve risks and uncertainties, including statements regarding the potential benefits and success of the drug or therapeutic. Actual results could differ materially from those anticipated in these forward-looking statements due to various factors, including but not limited to the risks and uncertainties associated with drug or device development and regulatory approval processes.
Viewers are advised content is for awareness and entertainment purposes only.
-
Michelle Fenwick – Northern Health
The outskirts of Melbourne is experiencing significant population growth over the next 10 years and Northern Health has taken preemptive steps to ensure the supply of new talented healthcare staff as well as develop the culture of the workplace.
Michelle Fenwick, the Executive Director of Northern Health spoke with our reporter Anne Dao on the challenges of this urban growth over the past 3 years. By 2031 the region is expected to increase in population by 63%. Added to this is hiring and training the right workforce to align with the clinical care needs of people coming into the healthcare centres.
Culture is forming in a growing organisation with approximately 70% of staff having been at Northern Health less than 4 years. However there is opportunity for clinical staff to accelerate their career in such an environment
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
-
New treatment options under investigation for pelvic organ prolapse
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
